Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care

Madhukar H. Trivedi, A. John Rush, Bradley N. Gaynes, Jonathan W. Stewart, Stephen R. Wisniewski, Diane Warden, Louise Ritz, James F. Luther, Diane Stegman, Joanne Deveaugh-Geiss, Robert Howland

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial required that antidepressant medication treatment be optimal regarding dose and duration, yet accommodate flexibility to ensure safety given the wide range of comorbid general medical and psychiatric disorders allowed in the trial. The objective of this study was to develop a measurement-based care (MBC) approach and an automated feedback system to ensure adequate and safe antidepressant treatment delivery suitable for both clinical research and routine practice. Ratings of depressive symptom severity and side-effect frequency, intensity, and burden were obtained at each treatment visit using the MBC system that (1) guided medication dose adjustments and treatment duration, (2) documented clinician adherence to treatment recommendations, and (3) provided prompt feedback to clinicians to enhance appropriate treatment decisions. Physician adherence to protocol-specific treatment was monitored based on measured symptoms and side-effect burden, and dose and duration of antidepressant at each critical decision point during the acute phase treatment of major depression. Feedback was provided at the point of care by the clinical coordinators, assisted by Web-based reports following each treatment visit. On the basis of the first treatment step with citalopram, over 85% of treatment encounters had appropriate fidelity to recommendations. Most deviations from treatment recommendations occurred late in treatment and were often justifiable. MBC proved to be feasible and effective in busy primary and psychiatric settings. This approach signals a paradigm shift toward the use of measurement-based clinical decisions, both at the point of care and following each visit, to deliver optimal pharmacotherapy for depression.

Original languageEnglish (US)
Pages (from-to)2479-2489
Number of pages11
JournalNeuropsychopharmacology
Volume32
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Controlled Clinical Trials
Depression
Therapeutics
Point-of-Care Systems
Antidepressive Agents
Psychiatry
Social Adjustment
Citalopram
Clinical Protocols
Comorbidity

Keywords

  • Adequate antidepressant treatment
  • Depression algorithm
  • Maximizing pharmacotherapy
  • Physician decision support
  • Symptom monitoring

ASJC Scopus subject areas

  • Pharmacology

Cite this

Maximizing the adequacy of medication treatment in controlled trials and clinical practice : STAR*D measurement-based care. / Trivedi, Madhukar H.; Rush, A. John; Gaynes, Bradley N.; Stewart, Jonathan W.; Wisniewski, Stephen R.; Warden, Diane; Ritz, Louise; Luther, James F.; Stegman, Diane; Deveaugh-Geiss, Joanne; Howland, Robert.

In: Neuropsychopharmacology, Vol. 32, No. 12, 12.2007, p. 2479-2489.

Research output: Contribution to journalArticle

Trivedi, MH, Rush, AJ, Gaynes, BN, Stewart, JW, Wisniewski, SR, Warden, D, Ritz, L, Luther, JF, Stegman, D, Deveaugh-Geiss, J & Howland, R 2007, 'Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care', Neuropsychopharmacology, vol. 32, no. 12, pp. 2479-2489. https://doi.org/10.1038/sj.npp.1301390
Trivedi, Madhukar H. ; Rush, A. John ; Gaynes, Bradley N. ; Stewart, Jonathan W. ; Wisniewski, Stephen R. ; Warden, Diane ; Ritz, Louise ; Luther, James F. ; Stegman, Diane ; Deveaugh-Geiss, Joanne ; Howland, Robert. / Maximizing the adequacy of medication treatment in controlled trials and clinical practice : STAR*D measurement-based care. In: Neuropsychopharmacology. 2007 ; Vol. 32, No. 12. pp. 2479-2489.
@article{8dd39b8bde3f421283b935177de7da6c,
title = "Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care",
abstract = "The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial required that antidepressant medication treatment be optimal regarding dose and duration, yet accommodate flexibility to ensure safety given the wide range of comorbid general medical and psychiatric disorders allowed in the trial. The objective of this study was to develop a measurement-based care (MBC) approach and an automated feedback system to ensure adequate and safe antidepressant treatment delivery suitable for both clinical research and routine practice. Ratings of depressive symptom severity and side-effect frequency, intensity, and burden were obtained at each treatment visit using the MBC system that (1) guided medication dose adjustments and treatment duration, (2) documented clinician adherence to treatment recommendations, and (3) provided prompt feedback to clinicians to enhance appropriate treatment decisions. Physician adherence to protocol-specific treatment was monitored based on measured symptoms and side-effect burden, and dose and duration of antidepressant at each critical decision point during the acute phase treatment of major depression. Feedback was provided at the point of care by the clinical coordinators, assisted by Web-based reports following each treatment visit. On the basis of the first treatment step with citalopram, over 85{\%} of treatment encounters had appropriate fidelity to recommendations. Most deviations from treatment recommendations occurred late in treatment and were often justifiable. MBC proved to be feasible and effective in busy primary and psychiatric settings. This approach signals a paradigm shift toward the use of measurement-based clinical decisions, both at the point of care and following each visit, to deliver optimal pharmacotherapy for depression.",
keywords = "Adequate antidepressant treatment, Depression algorithm, Maximizing pharmacotherapy, Physician decision support, Symptom monitoring",
author = "Trivedi, {Madhukar H.} and Rush, {A. John} and Gaynes, {Bradley N.} and Stewart, {Jonathan W.} and Wisniewski, {Stephen R.} and Diane Warden and Louise Ritz and Luther, {James F.} and Diane Stegman and Joanne Deveaugh-Geiss and Robert Howland",
year = "2007",
month = "12",
doi = "10.1038/sj.npp.1301390",
language = "English (US)",
volume = "32",
pages = "2479--2489",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Maximizing the adequacy of medication treatment in controlled trials and clinical practice

T2 - STAR*D measurement-based care

AU - Trivedi, Madhukar H.

AU - Rush, A. John

AU - Gaynes, Bradley N.

AU - Stewart, Jonathan W.

AU - Wisniewski, Stephen R.

AU - Warden, Diane

AU - Ritz, Louise

AU - Luther, James F.

AU - Stegman, Diane

AU - Deveaugh-Geiss, Joanne

AU - Howland, Robert

PY - 2007/12

Y1 - 2007/12

N2 - The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial required that antidepressant medication treatment be optimal regarding dose and duration, yet accommodate flexibility to ensure safety given the wide range of comorbid general medical and psychiatric disorders allowed in the trial. The objective of this study was to develop a measurement-based care (MBC) approach and an automated feedback system to ensure adequate and safe antidepressant treatment delivery suitable for both clinical research and routine practice. Ratings of depressive symptom severity and side-effect frequency, intensity, and burden were obtained at each treatment visit using the MBC system that (1) guided medication dose adjustments and treatment duration, (2) documented clinician adherence to treatment recommendations, and (3) provided prompt feedback to clinicians to enhance appropriate treatment decisions. Physician adherence to protocol-specific treatment was monitored based on measured symptoms and side-effect burden, and dose and duration of antidepressant at each critical decision point during the acute phase treatment of major depression. Feedback was provided at the point of care by the clinical coordinators, assisted by Web-based reports following each treatment visit. On the basis of the first treatment step with citalopram, over 85% of treatment encounters had appropriate fidelity to recommendations. Most deviations from treatment recommendations occurred late in treatment and were often justifiable. MBC proved to be feasible and effective in busy primary and psychiatric settings. This approach signals a paradigm shift toward the use of measurement-based clinical decisions, both at the point of care and following each visit, to deliver optimal pharmacotherapy for depression.

AB - The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial required that antidepressant medication treatment be optimal regarding dose and duration, yet accommodate flexibility to ensure safety given the wide range of comorbid general medical and psychiatric disorders allowed in the trial. The objective of this study was to develop a measurement-based care (MBC) approach and an automated feedback system to ensure adequate and safe antidepressant treatment delivery suitable for both clinical research and routine practice. Ratings of depressive symptom severity and side-effect frequency, intensity, and burden were obtained at each treatment visit using the MBC system that (1) guided medication dose adjustments and treatment duration, (2) documented clinician adherence to treatment recommendations, and (3) provided prompt feedback to clinicians to enhance appropriate treatment decisions. Physician adherence to protocol-specific treatment was monitored based on measured symptoms and side-effect burden, and dose and duration of antidepressant at each critical decision point during the acute phase treatment of major depression. Feedback was provided at the point of care by the clinical coordinators, assisted by Web-based reports following each treatment visit. On the basis of the first treatment step with citalopram, over 85% of treatment encounters had appropriate fidelity to recommendations. Most deviations from treatment recommendations occurred late in treatment and were often justifiable. MBC proved to be feasible and effective in busy primary and psychiatric settings. This approach signals a paradigm shift toward the use of measurement-based clinical decisions, both at the point of care and following each visit, to deliver optimal pharmacotherapy for depression.

KW - Adequate antidepressant treatment

KW - Depression algorithm

KW - Maximizing pharmacotherapy

KW - Physician decision support

KW - Symptom monitoring

UR - http://www.scopus.com/inward/record.url?scp=34250843222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250843222&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301390

DO - 10.1038/sj.npp.1301390

M3 - Article

C2 - 17406651

AN - SCOPUS:34250843222

VL - 32

SP - 2479

EP - 2489

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 12

ER -